Amniotics' CEO Marcus Larsson gives an update and talks about the way forward before the subscription period for the company's warrant TO3 begins. https://lnkd.in/dt5HZQk3
Amniotics AB
Forskning inom bioteknik
Lund, Skåne 2 234 följare
Amniotics AB develops tissue-specific mesenchymal stem cells for regenerative medicine. #celltherapy #stemcells
Om oss
Amniotics was born out of the discovery of novel stem cells in full term amniotic fluid. Research on these cells has demonstrated a number of unique properties in them, highlighting their extraordinary suitability for medical applications. These properties, in combination with safe collection, ethical agreeability, tissues and high cell counts harbour the promise of the exciting journey we have started pushing medical boundaries. The science and research behind the discoveries on which the company is based has been carried out within the realms of the reputable Lund University in southern Sweden, one of its prime research centers BMC (Bio Medical Center) Research Center, and the university hospital in Lund. Therefore, Amniotics considers itself today to be uniquely positioned to translate stem cell technologies into novel and improved human therapeutics. Our ultimate vision is to contribute to the successful treatment of serious human diseases by providing the very best cells for various regenerative medical applications. The fact that our cells are of neonatal source (and safely retrieved from the amniotic fluid from C-sections), means that they have greater genome integrity. And also other positive attributes of the neonatal source of our cells makes them superior to traditional sources of stem cells that are currently in therapeutic use. As part of our commitment to providing the best cell therapeutics we are developing these for treatments with high unmet needs in collaboration with international renowned KOLs and partners. In a nutshell, we have designed and built a complete ecosystem for managing these cells in a safe, secure and controlled manner, which we are now expanding and scaling up. Our journey continues. We will push the boundaries of science within regenerative medicine to save and improve the lives of many. #regenerativemedicine, #stemcells #therapies
- Webbplats
-
http://www.amniotics.com/
Extern länk för Amniotics AB
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Lund, Skåne
- Typ
- Privatägt företag
- Grundat
- 2015
- Specialistområden
- Life science, Stem cell, MSC, cell therapy, IPS, Pulmonary Diseases, Pulmonary Surfactant, regenerative medicine, COVID-19 och IPF
Adresser
-
Primär
Scheelevägen 2
Building 406
Lund, Skåne 22381, SE
Anställda på Amniotics AB
Uppdateringar
-
CEO Marcus Larsson presents at Redeye Regenerative Medicine/Cell Therapy Event https://lnkd.in/dBkJJJf2
-
-
Amniotics AB omdelade detta
Amniotics has raised in total SEK 25m in a rights issue where Redeye acted as Sole Lead Manager and Bookrunner. Congratulations to the Amniotics AB team! Amniotics AB (publ) is a clinical-stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking. Amniotics has an established and approved GMP-facility. Which opens up for Contract Development and Manufacturing Organization (CDMO) for other biotech companies. Amniotics is headquartered in Lund, Sweden.
-
-
Amniotics COO will present at the 3rd Allogeneic Cell Therapies Summit in London. https://ter.li/v7pb80
Allogeneic Cell Therapies Summit Europe 2022 | Online Digital Even
allogeneic-cell-therapies-europe.com